ArticleHepatology international2026

Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study".

Huikang Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.